vs
QuidelOrtho Corp（QDEL）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是Alpha Teknova, Inc.的70.1倍（$699.9M vs $10.0M）。Alpha Teknova, Inc.净利率更高（-47.7% vs -104.7%，领先57.1%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -3.7%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-94.7M）。过去两年Alpha Teknova, Inc.的营收复合增速更高（3.7% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
QDEL vs TKNO — 直观对比
营收规模更大
QDEL
是对方的70.1倍
$10.0M
营收增速更快
TKNO
高出11.5%
-3.7%
净利率更高
TKNO
高出57.1%
-104.7%
自由现金流更多
TKNO
多$93.9M
$-94.7M
两年增速更快
TKNO
近两年复合增速
-2.9%
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $10.0M |
| 净利润 | $-733.0M | $-4.8M |
| 毛利率 | — | 32.5% |
| 营业利润率 | -100.7% | -46.2% |
| 净利率 | -104.7% | -47.7% |
| 营收同比 | -3.7% | 7.8% |
| 净利润同比 | -3583.4% | 16.8% |
| 每股收益（稀释后） | $-10.78 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELTKNO
| Q4 25 | — | $10.0M | ||
| Q3 25 | $699.9M | $10.5M | ||
| Q2 25 | $613.9M | $10.3M | ||
| Q1 25 | $692.8M | $9.8M | ||
| Q4 24 | $707.8M | $9.3M | ||
| Q3 24 | $727.1M | $9.6M | ||
| Q2 24 | $637.0M | $9.6M | ||
| Q1 24 | $711.0M | $9.3M |
净利润QDELTKNO
| Q4 25 | — | $-4.8M | ||
| Q3 25 | $-733.0M | $-4.3M | ||
| Q2 25 | $-255.4M | $-3.6M | ||
| Q1 25 | $-12.7M | $-4.6M | ||
| Q4 24 | $-178.4M | $-5.7M | ||
| Q3 24 | $-19.9M | $-7.6M | ||
| Q2 24 | $-147.7M | $-5.4M | ||
| Q1 24 | $-1.7B | $-8.1M |
毛利率QDELTKNO
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 23.8% |
营业利润率QDELTKNO
| Q4 25 | — | -46.2% | ||
| Q3 25 | -100.7% | -38.4% | ||
| Q2 25 | -29.4% | -32.9% | ||
| Q1 25 | 4.7% | -50.7% | ||
| Q4 24 | -14.2% | -60.7% | ||
| Q3 24 | 2.1% | -77.6% | ||
| Q2 24 | -18.4% | -53.0% | ||
| Q1 24 | -247.3% | -86.0% |
净利率QDELTKNO
| Q4 25 | — | -47.7% | ||
| Q3 25 | -104.7% | -41.0% | ||
| Q2 25 | -41.6% | -34.7% | ||
| Q1 25 | -1.8% | -47.4% | ||
| Q4 24 | -25.2% | -61.7% | ||
| Q3 24 | -2.7% | -79.0% | ||
| Q2 24 | -23.2% | -55.8% | ||
| Q1 24 | -239.9% | -87.2% |
每股收益（稀释后）QDELTKNO
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-10.78 | $-0.08 | ||
| Q2 25 | $-3.77 | $-0.07 | ||
| Q1 25 | $-0.19 | $-0.09 | ||
| Q4 24 | $-2.54 | $-0.09 | ||
| Q3 24 | $-0.30 | $-0.15 | ||
| Q2 24 | $-2.20 | $-0.13 | ||
| Q1 24 | $-25.50 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $21.3M |
| 总债务越低越好 | $2.5B | $13.1M |
| 股东权益账面价值 | $2.0B | $68.8M |
| 总资产 | $5.7B | $103.6M |
| 负债/权益比越低杠杆越低 | 1.23× | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资QDELTKNO
| Q4 25 | — | $21.3M | ||
| Q3 25 | $98.1M | $22.1M | ||
| Q2 25 | $151.7M | $24.0M | ||
| Q1 25 | $127.1M | $26.3M | ||
| Q4 24 | $98.3M | $30.4M | ||
| Q3 24 | $143.7M | $31.7M | ||
| Q2 24 | $107.0M | $18.6M | ||
| Q1 24 | $78.5M | $21.6M |
总债务QDELTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | $2.5B | $13.1M | ||
| Q2 25 | $2.1B | $13.0M | ||
| Q1 25 | $2.1B | $13.0M | ||
| Q4 24 | $2.1B | $9.4M | ||
| Q3 24 | $2.2B | $10.9M | ||
| Q2 24 | $2.2B | $12.3M | ||
| Q1 24 | $2.2B | $13.2M |
股东权益QDELTKNO
| Q4 25 | — | $68.8M | ||
| Q3 25 | $2.0B | $72.7M | ||
| Q2 25 | $2.8B | $76.1M | ||
| Q1 25 | $3.0B | $78.6M | ||
| Q4 24 | $3.0B | $82.4M | ||
| Q3 24 | $3.2B | $87.3M | ||
| Q2 24 | $3.2B | $78.9M | ||
| Q1 24 | $3.3B | $83.4M |
总资产QDELTKNO
| Q4 25 | — | $103.6M | ||
| Q3 25 | $5.7B | $107.6M | ||
| Q2 25 | $6.4B | $110.5M | ||
| Q1 25 | $6.5B | $114.0M | ||
| Q4 24 | $6.4B | $118.8M | ||
| Q3 24 | $6.8B | $124.1M | ||
| Q2 24 | $6.7B | $115.4M | ||
| Q1 24 | $6.7B | $120.8M |
负债/权益比QDELTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | 1.23× | 0.18× | ||
| Q2 25 | 0.74× | 0.17× | ||
| Q1 25 | 0.70× | 0.17× | ||
| Q4 24 | 0.72× | 0.11× | ||
| Q3 24 | 0.68× | 0.12× | ||
| Q2 24 | 0.70× | 0.16× | ||
| Q1 24 | 0.68× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $-810.0K |
| 自由现金流率自由现金流/营收 | -13.5% | -8.1% |
| 资本支出强度资本支出/营收 | 7.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流QDELTKNO
| Q4 25 | — | $-462.0K | ||
| Q3 25 | $-45.5M | $-2.0M | ||
| Q2 25 | $-46.8M | $-2.1M | ||
| Q1 25 | $65.6M | $-4.1M | ||
| Q4 24 | $63.7M | $-936.0K | ||
| Q3 24 | $117.9M | $-2.1M | ||
| Q2 24 | $-97.9M | $-2.8M | ||
| Q1 24 | $-700.0K | $-6.6M |
自由现金流QDELTKNO
| Q4 25 | — | $-810.0K | ||
| Q3 25 | $-94.7M | $-2.4M | ||
| Q2 25 | $-84.3M | $-2.3M | ||
| Q1 25 | $9.4M | $-4.3M | ||
| Q4 24 | $16.5M | $-1.5M | ||
| Q3 24 | $71.4M | $-2.4M | ||
| Q2 24 | $-133.2M | $-3.0M | ||
| Q1 24 | $-66.8M | $-6.7M |
自由现金流率QDELTKNO
| Q4 25 | — | -8.1% | ||
| Q3 25 | -13.5% | -22.6% | ||
| Q2 25 | -13.7% | -22.4% | ||
| Q1 25 | 1.4% | -44.0% | ||
| Q4 24 | 2.3% | -16.2% | ||
| Q3 24 | 9.8% | -25.0% | ||
| Q2 24 | -20.9% | -30.7% | ||
| Q1 24 | -9.4% | -71.8% |
资本支出强度QDELTKNO
| Q4 25 | — | 3.5% | ||
| Q3 25 | 7.0% | 3.7% | ||
| Q2 25 | 6.1% | 2.0% | ||
| Q1 25 | 8.1% | 2.1% | ||
| Q4 24 | 6.7% | 6.1% | ||
| Q3 24 | 6.4% | 3.5% | ||
| Q2 24 | 5.5% | 1.2% | ||
| Q1 24 | 9.3% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
